
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is a biopharmaceutical company with a positive outlook, driven by its promising product candidates, vilobelimab and izicopan, which target the C5a/C5aR pathway to treat autoimmune and inflammatory diseases. The company recently announced positive 1Q26 earnings and is expected to have enough cash to fund its operations through 2029. In addition to AAV, the company plans to evaluate izicopan's efficacy in various inflammatory renal diseases, providing multiple potential opportunities for success. However, there are risks to consider, such as clinical trial failures and difficulty in demonstrating superiority over current standard of care treatments. Overall, InflaRx's strong clinical focus, potential partnerships, and successful development of its C5a/C5aR inhibitors make it an attractive investment opportunity.
Bears say
InflaRx is a clinical-stage biotechnology company with a focus on developing anti-inflammatory therapeutics targeting the C5a/C5aR complement pathway. The company has a limited commercialization for its COVID treatment and is currently in a Phase 2a basket study for its C5aR inhibitor in CSU and HS. However, their increased pursuit of development in ANCA vasculitis may pose potential financial risks and uncertainties, making us maintain our negative outlook on their stock.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares